slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,138
Current window 65,311-65,340
Pages 2,605
Rows per page 30
Component
65,311-65,340 of 78,138
16
The 2Q23 spike is driven by a large Goodwill impairment charge.HomeStreet | Results Presentation Deck | 36 slides · HomeStreet
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain1 hit
19
The slide uses a series of donut charts to show geographic concentration per asset class, followed by tables of loan characteristics and financial metrics.HomeStreet | Results Presentation Deck | 36 slides · HomeStreet
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain1 hit
20
The slide uses a series of donut charts to show geographic distribution across five loan categories, followed by detailed loan characteristics and financial metrics for each.HomeStreet | Results Presentation Deck | 36 slides · HomeStreet
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain1 hit
22
The chart displays 9 distinct industry segments with their respective percentage contributions to the total balance.HomeStreet | Results Presentation Deck | 36 slides · HomeStreet
Conference presentation Investor relations Beat · SatisfactionLoop · Logic Chain1 hit
13
The chart uses a concentric semi-circle design to represent market layers, with a specific focus on HD trucking as the core.Hyzon | Investor Conference Presentation Deck | 20 slides · Hyzon
Conference presentation Investor relations Beat · Rising Success1 hit
11
Includes citations from Nature Signal Transduction and Targeted Therapy and Nature Medicine.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
12
The slide uses a combination of bar charts for preclinical data and a summary table for clinical outcomes to demonstrate the superiority of NXC-201.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
13
The slide highlights the structural advantage of the HSL configuration using a (GGGGS)5 linker.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
15
The slide highlights a significant difference in neurotoxicity percentages (4% vs 23-28%) and CRS onset/duration metrics.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
18
The chart illustrates the pharmacokinetics of the NXC-201 (HBI0101) therapy, highlighting a 30-day clearance window.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Solution & Approach1 hit
22
The slide uses a grouped bar chart to compare hematologic response and cardiac response (NT-proBNP reduction) across four treatment categories.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
23
The slide uses a visual timeline/chart hybrid to compare CAR-T cell expansion, sBCMA reduction, and side effect durations (CRS and ICANS) across three products.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
24
The slide uses a table structure to contrast treatment landscapes and patient outcomes, with a bar chart at the bottom illustrating patient growth.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
25
The slide uses a visual bridge to highlight a 67% improvement in response rates for NXC-201 compared to the average of the three competitors shown.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
28
Includes detailed source citations in the footer.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Why Now1 hit
31
Includes a comparative table of clinical outcomes (ORR/CR/sCR) for NXC-201 vs. competitors.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
32
The slide uses a wave-like visual to represent market segments and their associated dollar values.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & ProofLoop · Quick Win Big Bet1 hit
35
The chart compares NXC-201 against other therapies categorized by prior BCMA treatment status.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Evidence & Proof1 hit
37
The chart illustrates deepening responses in patients treated with NXC-201 over time.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
48
The slide uses a bar chart to contrast the combined annual sales of two groups of oncology drugs.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
53
The slide uses a scatter plot to map clinical trials and a table to detail standard-of-care metrics by line of therapy.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
54
The slide compares clinical outcomes for patients across different lines of treatment, emphasizing high disease control and zero drug-related toxicity.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
59
The slide compares efficacy data for Humira, Stelara, and Entyvio against their respective placebo groups.Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
62
The process is presented as a non-linear, snake-like flow (1-5 left-to-right, 6-10 right-to-left).Immix Biopharma | Investor Presentation Deck | 64 slides · Immix Biopharma
Deck Investor relations Beat · Impact & Next Steps1 hit
25
Includes a table of liquidity sources and a grouped bar chart showing coverage ratios.Independent Bank Corp | Results Presentation Deck | 30 slides · Independent Bank Corp
Conference presentation Investor relations 1 hit
08
Includes a bar chart for CASM growth and a table for ASM growth, alongside bulleted strategic updates.jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
09
The slide uses a stacked bar chart to visualize the deferral of capex against a revised forecast.jetBlue | Results Presentation Deck | 17 slides · JetBlue
Conference presentation Investor relations Beat · SatisfactionLoop · Cost Of Inaction1 hit
06
The chart shows a stacked bar chart for loan composition (Consumer vs Commercial) with an overlaid line chart for Loan Yield.KeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
07
The chart combines a stacked bar chart for deposit segments with a line chart for deposit cost in basis points.KeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit
15
The chart combines a bar chart for NII and a line chart for NIM (Net Interest Margin).KeyCorp | Results Presentation Deck | 30 slides · KeyCorp
Conference presentation Investor relations Beat · EvidenceLoop · Logic Chain1 hit